PCSK9 inhibitors: Potential in cardiovascular therapeutics

Current Cardiology Reports

Volumn 15, Issue 3, 2013, Pages

  Do, Rose Q ^a,b   Vogel, Robert A ^a,b   Schwartz, Gregory G ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antisense; LDL cholesterol; LDL receptor; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ALIROCUMAB; ANTISENSE OLIGONUCLEOTIDE; ATORVASTATIN; BOCOCIZUMAB; EPIDERMAL GROWTH FACTOR; EVOLOCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LGT 209; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MONOCLONAL ANTIBODY; PEGDINETANIB; PLACEBO; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9; PROPROTEIN CONVERTASE SUBTILISIN KEXIN 9 INHIBITOR; ROSUVASTATIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANTISENSE THERAPY; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BINDING COMPETITION; BINDING SITE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG SAFETY; ENZYME ACTIVITY; ENZYME INHIBITION; GAIN OF FUNCTION MUTATION; GENE SILENCING; HUMAN; ISCHEMIC HEART DISEASE; LOSS OF FUNCTION MUTATION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN DEGRADATION; PROTEIN METABOLISM; RECEPTOR UPREGULATION; RISK REDUCTION; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 84872307169     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-012-0345-z     Document Type: Article

References (82)

1. Wilson PW, Garrison RJ, Castelli WP, Feinleib M, McNamara PM, Kannel WB. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980;46:649-54. (Pubitemid 10009820)
2. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebocontrolled trial. Lancet 2002;360:7-22.
3. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-Analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670-81. A meta-Analysis indicating that more intensive statin therapy, resulting in greater LDL-C reduction, is associated with cardiovascular risk reduction compared with less intensive statin therapy, even when LDL-C level on less intensive therapy is below 2 mmol/L.
4. O'Keefe Jr JH, Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-6. (Pubitemid 38686815)
5. Glueck CJ, Kelley W, Gupta A, Fontaine RN, Wang P, Gartside PS. Prospective 10-year evaluation of hypobetalipoproteinemia in a cohort of 772 firefighters and cross-sectional evaluation of hypocholesterolemia in 1,479 men in the National Health and Nutrition Examination Survey I. Metabolism. 1997;46:625-33. (Pubitemid 27247295)
6. Wiviott SD, Cannon CP, Morrow DA, Ray KK, Pfeffer MA, Braunwald E. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol. 2005;46:1411-6. (Pubitemid 41446174)
7. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining lowdensity lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). J Am Coll Cardiol. 2011 57: 1666-75
8. Cannon CP, Giugliano RP, Blazing MA, et al. Rationale and design of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): comparison of ezetimbe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndromes. Am Heart J. 2008;156:826-32.
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-39. (Pubitemid 38924592)
10. Karalis DG, Victor B, Ahedor L, Liu L. Use of lipid-lowering medications and the likelihood of achieving optimal LDLcholesterol goals in coronary artery disease patients. Cholesterol. 2012;2012:861-924.
11. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in get with the guidelines. Am Heart J. 2009;157:111-7.
12. Kotseva K, Wood D, De BG, De BD, Pyorala K, Keil U. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil. 2009;16:121-37. A large multinational survey of primary and secondary cardiovascular prevention measures demonstrating that a large proportion of patients still do not reach targets for total or LDL cholesterol.
13. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-Analysis of randomised statin trials. Lancet. 2010;375:735-42.
14. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, Alderman M, Ridker PM. Statin therapy and risk of developing type 2 diabetes: a meta-Analysis. Diabetes Care. 2009;32:1924-9.
15. Charles EC, Olson KL, Sandhoff BG, McClure DL, Merenich JA. Evaluation of cases of severe statin-related transaminitis within a large health maintenance organization. Am J Med. 2005;118:618-24. (Pubitemid 40732701)
16. McKenney JM, Koren MJ, Kereiakes DJ, Hanotin C, Ferrand AC, Stein EA. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012;59:2344-53. A phase II trial demonstrating that parenteral administration of a fully human monoclonal antibody to PCSK9 produced 40-70 % reduction in LDL cholesterol from baseline levels on stable atorvastatin therapy.
17. Goldstein JL, Brown MS. The LDL receptor. Arterioscler Thromb Vasc Biol. 2009;29:431-8. A historical review of the discovery of the LDL receptor by two Nobel Prize laureates, which led to new ways of thinking about cholesterol metabolism and the discovery of statins. This pioneering work led to new concepts of receptor-mediated endocytosis, receptor recycling, and feedback regulation of receptors.
18. Akram ON, Bernier A, Petrides F, Wong G, Lambert G. Beyond LDL cholesterol, a new role for PCSK9. Arterioscler Thromb Vasc Biol. 2010;30:1279-81.
19. Ferri N, Tibolla G, Pirillo A, et al. Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Atherosclerosis. 2012;220:381-6.
20. Wu CY, Tang ZH, Jiang L, Li XF, Jiang ZS, Liu LS. PCSK9 siRNA inhibits HUVEC apoptosis induced by ox-LDL via Bcl/Bax-caspase9-caspase3 pathway. Mol Cell Biochem. 2012;359:347-58.
21. Denis M, Marcinkiewicz J, Zaid A, et al. Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation. 2012;125:894-901.
22. Davignon J, Dubuc G, Seidah NG. The influence of PCSK9 polymorphisms on serum low-density lipoprotein cholesterol and risk of atherosclerosis. Curr Atheroscler Rep. 2010;12:308-15.
23. Abifadel M, Varret M, Rabes JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154-6. (Pubitemid 36666925)
24. Naoumova RP, Tosi I, Patel D, et al. Severe hypercholesterolemia in four British families with the D374Y mutation in the PCSK9 gene: long-Term follow-up and treatment response. Arterioscler Thromb Vasc Biol. 2005;25:2654-60. (Pubitemid 43732293)
25. Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-72.
26. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al. Molecular characterization of loss-of-functionmutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet. 2006;79:514-23. (Pubitemid 44384260)
27. Yue P, Averna M, Lin X, Schonfeld G. The c.43-44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population. Hum Mutat. 2006;27:460-6. (Pubitemid 43673333)
28. Cariou B, Ouguerram K, Zair Y, et al. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia. Arterioscler Thromb Vasc Biol. 2009;29:2191-7. In examining a French family with familial hypobetalipoproteinemia, this study is the first demonstration of increased LDL catabolism in humans with PCSK9 LOF mutations.
29. Hooper AJ, Marais AD, Tanyanyiwa DM, Burnett JR. The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population. Atherosclerosis. 2007;193:445-8. References 27-30. (Pubitemid 47058112)
30. Shan L, Pang L, Zhang R, Murgolo NJ, Lan H, Hedrick JA. PCSK9 binds to multiple receptors and can be functionally inhibited by an EGF-A peptide. Biochem Biophys Res Commun. 2008;375:69-73.
31. McNutt MC, Kwon HJ, Chen C, Chen JR, Horton JD, Lagace TA. Antagonism of secreted PCSK9 increases low density lipoprotein receptor expression in HepG2 cells. J Biol Chem. 2009;284:10561-70.
32. Du F, Hui Y, Zhang M, Linton MF, Fazio S, Fan D. Novel domain interaction regulates secretion of proprotein convertase subtilisin/kexin type 9 (PCSK9) protein. J Biol Chem. 2011;286:43054-61.
33. Lipovsek D. Adnectins: engineered target-binding protein therapeutics. Protein Eng Des Sel. 2011;24:3-9.
34. McNutt MC, Lagace TA, Horton JD. Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells. J Biol Chem. 2007;282:20799-803. (Pubitemid 47099894)
35. Benjannet S, Hamelin J, Chretien M, Seidah NG. Loss-And gainof-function PCSK9 variants: cleavage specificity, dominant negative effects, and low density lipoprotein receptor (LDLR) degradation. J Biol Chem. 2012;287:33745-55.
36. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J. 2012;33:1142-9.
37. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375:998-1006.
38. Graham MJ, Lemonidis KM, Whipple CP, et al. Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res. 2007;48:763-7. (Pubitemid 46557881)
39. Nielsen CB, Singh SK, Wengel J, Jacobsen JP. The solution structure of a locked nucleic acid (LNA) hybridized to DNA. J Biomol Struct Dyn. 1999;17:175-91. (Pubitemid 29510977)
40. Straarup EM, Fisker N, Hedtjarn M, et al. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res. 2010;38:7100-11.
41. Gupta N, Fisker N, Asselin MC, et al. A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS One. 2010;5: e10682. The first study to demonstrate efficacy of a potent, high affinity locked nucleic acid antisense oligonucleotide in PCSK9 inhibition. It reduced PCSK9 mRNA and protein in human and mouse cell culture lines and upregulated hepatic LDLR in mice in vivo.
42. Lindholm MW, Elmen J, Fisker N, et al. PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates. Mol Ther. 2012;20:376-81.
43. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A. 2008;105:11915-20.
44. Maxwell KN, Breslow JL. Antibodies to PCSK9: a superior way to lower LDL cholesterol? Circ Res. 2012;111:274-7. Commentary on the current status of PCSK9 inhibition therapies.
45. Giugliano RP, Desai NR, Kohli P, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012;380(9858):2007-17. The largest phase 2 trial of a PCSK9 antibody to date. It evaluated AMG 145 or placebo in 631 subjects with hypercholesterolemia on stable dose of statin with or without ezetimibe.
46. Koren MJ, Scott R, Kim JB, et al. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2012;380(9858):1995- 2006. Placebo-controlled phase 2 study evaluating AMG 145 in 406 patients with hypercholesterolemia who were not already on lipid-lowering therapy.
47. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation. 2012;126:2408-17. Phase 2 multicenter, placebocontrolled trial evaluating AMG 145 administered every 4 weeks in 167 patients with heterozygous familial hypercholesterolemia on background lipid-lowering therapies. AMG 145 reduced LDL-C by 43-55 %.
48. Roth EM, McKenney JM, Hanotin C, Asset G, Stein EA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367:1891-900. Phase 2 placebo-controlled trial of REGN727/SAR236553 in 92 subjects with primary hypercholesterolemia treated with atorvastatin.
49. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce lowdensity lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised controlled trial. Lancet. 2012;380:29-36. Report of a phase 2, multicenter, placebocontrolled trial evaluating the effect of REGN727/SAR236553 at different dosing regimens added to background therapy with statin with or without ezetimibe.
50. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012. doi:10.1001/jama.2012.25790. Phase 2 placebo-controlled clinical trial evaluating AMG 145 in 157 subjects unable to take or uptitrate statins due to myalgias or myopathy. AMG 145 was well tolerated in most patients and produced reductions in LDL-C of 41-63 %.
51. Chan JC, Piper DE, Cao Q, et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci U S A. 2009;106:9820-5. The first anti-PCSK9 antibody, tested in cynomolgus monkeys, with a single intravenous administration resulting in LDL-C reduction of 80 %.
52. Ni YG, Di MS, Condra JH, et al. A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo. J Lipid Res. 2011;52:78-86.
53. Zhang L, McCabe T, Condra JH, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012;8:310-27.
54. Liang H, Chaparro-Riggers J, Strop P, et al. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-Treated hypercholesterolemic nonhuman primates. J Pharmacol Exp Ther. 2012;340:228-36.
55. Chaparro-Riggers J, Liang H, DeVay RM, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012;287:11090-7.
56. Dias CS, Shaywitz AJ, Wasserman SM, et al. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins. J Am Coll Cardiol. 2012;60:1888-98.
57. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012;366:1108-18. Report of three phase 1 trials testing fully human PCSK9 antibody REGN727/SAR236553 in healthy subjects, and in subjects with familial or non-familial hypercholesterolemia.
58. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated Creactive protein. N Engl J Med. 2008;359:2195-207.
59. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-35. (Pubitemid 40471450)
60. Lewington S, Whitlock G, Clarke R, et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-Analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007;370:1829-39.
61. Amarenco P, Bogousslavsky J, Callahan III A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-59. (Pubitemid 44202151)
62. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-Analysis of 31 randomized controlled trials. Stroke. 2012;43:2149-56. A meta-Analysis indicating lack of relationship between statin therapy and risk of hemorrhagic stroke.
63. McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. Cochrane Database Syst Rev. 2010;(8):CD007514.
64. Seidah NG, Benjannet S, Wickham L, et al. The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation. Proc Natl Acad Sci U S A. 2003;100:928-33. (Pubitemid 36183932)
65. Heikkila P, Kahri AI, Ehnholm C, Kovanen PT. The effect of low-And high-density lipoprotein cholesterol on steroid hormone production and ACTH-induced differentiation of rat adrenocortical cells in primary culture. Cell Tissue Res. 1989;256:487-94. (Pubitemid 19152875)
66. Jenkins DJ, Kendall CW, Nguyen TH, et al. Effect on hematologic risk factors for coronary heart disease of a cholesterol reducing diet. Eur J Clin Nutr. 2007;61:483-92. (Pubitemid 46605219)
67. Yavuz B, Ertugrul DT, Cil H, et al. Increased levels of 25 hydroxyvitamin D and 1,25-dihydroxyvitamin D after rosuvastatin treatment: a novel pleiotropic effect of statins? Cardiovasc Drugs Ther. 2009;23:295-9.
68. Roubtsova A, Munkonda MN, Awan Z, et al. Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue. Arterioscler Thromb Vasc Biol. 2011;31:785-91.
69. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. Hepatology. 2008;48:646-54.
70. Spady DK, Bilheimer DW, Dietschy JM. Rates of receptordependent and -independent low density lipoprotein uptake in the hamster. Proc Natl Acad Sci U S A. 1983;80:3499-503. (Pubitemid 13060191)
71. Le MC, Kourimate S, Langhi C, et al. Proprotein convertase subtilisin kexin type 9 null mice are protected from postprandial triglyceridemia. Arterioscler Thromb Vasc Biol. 2009;29:684-90.
72. Leblond F, Seidah NG, Precourt LP, Delvin E, Dominguez M, Levy E. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2009;296:G805-15.
73. Mbikay M, Sirois F, Mayne J, et al. PCSK9-deficient mice exhibit impaired glucose tolerance and pancreatic islet abnormalities. FEBS Lett. 2010;584:701-6.
74. Labonte P, Begley S, Guevin C, et al. PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression. Hepatology. 2009;50:17-24.
75. Poirier S, Prat A, Marcinkiewicz E, et al. Implication of the proprotein convertase NARC-1/PCSK9 in the development of the nervous system. J Neurochem. 2006;98:838-50. (Pubitemid 44051284)
76. Kysenius K, Muggalla P, Matlik K, Arumae U, Huttunen HJ. PCSK9 regulates neuronal apoptosis by adjusting ApoER2 levels and signaling. Cell Mol Life Sci. 2012;69:1903-16.
77. Ranheim T, Mattingsdal M, Lindvall JM, et al. Genome-wide expression analysis of cells expressing gain of function mutant D374Y-PCSK9. J Cell Physiol. 2008;217:459-67.
78. Lan H, Pang L, Smith MM, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9) affects gene expression pathways beyond cholesterolmetabolism in liver cells. J Cell Physiol. 2010;224:273-81.
79. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB, Greten H. Safety and efficacy of Atorvastatin-induced very low-density lipoprotein cholesterol levels in Patients with coronary heart disease (a post hoc analysis of the treating to new targets [TNT] study). Am J Cardiol. 2007;100:747-52. (Pubitemid 47271930)
80. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363:2406-15.
81. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306:2099-109.
82. Lambert G, Sjouke B, Choque B, Kastelein JJ, Hovingh GK. The PCSK9 decade. J Lipid Res. 2012;53:2515-24.